Abstract
Fondaparinux is a synthetic, five-saccharide chain, AT-dependent, anti-FXa agent. Studies showed that fondaparinux acts in prevention and treatment of venous thromboembolism and in ischemic heart disease, without significant bleeding risk. The drug inhibits thrombin generation, has long half-life and can be administered once-daily without laboratory monitoring. It may be used in HIT treatment.
Keywords: Antithrombotic, factor Xa inhibitor, heparin, low molecular weight heparin, fondaparinux
Mini-Reviews in Medicinal Chemistry
Title: Fondaparinux: Pharmacology and Clinical Experience in Cardiovascular Medicine
Volume: 7 Issue: 4
Author(s): V. Toschi and M. Lettino
Affiliation:
Keywords: Antithrombotic, factor Xa inhibitor, heparin, low molecular weight heparin, fondaparinux
Abstract: Fondaparinux is a synthetic, five-saccharide chain, AT-dependent, anti-FXa agent. Studies showed that fondaparinux acts in prevention and treatment of venous thromboembolism and in ischemic heart disease, without significant bleeding risk. The drug inhibits thrombin generation, has long half-life and can be administered once-daily without laboratory monitoring. It may be used in HIT treatment.
Export Options
About this article
Cite this article as:
Toschi V. and Lettino M., Fondaparinux: Pharmacology and Clinical Experience in Cardiovascular Medicine, Mini-Reviews in Medicinal Chemistry 2007; 7 (4) . https://dx.doi.org/10.2174/138955707780363819
DOI https://dx.doi.org/10.2174/138955707780363819 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Roles of MicroRNAs in Atherosclerosis
Current Medicinal Chemistry Ezetimibe Therapy for Dyslipidemia: An Update
Current Pharmaceutical Design Preface
Current Drug Targets - Infectious Disorders Chymase as an Important Target for Preventing Complications of Metabolic Syndrome
Current Medicinal Chemistry Inhibition of Renin-Angiotensin System and Advanced Glycation End Products Formation: A Promising Therapeutic Approach Targeting on Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Population Approaches for Detecting Glucose Disorders
Current Diabetes Reviews Experimental Benefits of Sex Hormones on Vascular Function and the Outcome of Hormone Therapy in Cardiovascular Disease
Current Cardiology Reviews Validity of Oxygen-Ozone Therapy as Integrated Medication Form in Chronic Inflammatory Diseases
Cardiovascular & Hematological Disorders-Drug Targets Inhibition of Platelet Adhesion to Collagen as a New Target for Antithrombotic Drugs
Current Drug Targets - Cardiovascular & Hematological Disorders When Cells Become a Drug. Endothelial Progenitor Cells for Cardiovascular Therapy: Aims and Reality
Recent Patents on Cardiovascular Drug Discovery Material-Based Engineering Strategies for Cardiac Regeneration
Current Pharmaceutical Design Emerging Targets for the Treatment of Dyslipidemia
Current Medicinal Chemistry Contemporary Treatment of Amyloid Heart Disease
Current Pharmaceutical Design Antioxidative Properties of Flavonoids
Current Organic Chemistry Salusins in Hypertension and Related Cardiovascular Diseases
Current Drug Metabolism Chemistry and Applications of 4-Hydroxyquinolin-2-one and Quinoline-2,4-dionebased Compounds
Current Organic Chemistry Dyslipidemia and Cardiovascular Disease Prevention in South Asians: A Review and Discussion of Causes, Challenges and Management Strategies
Current Diabetes Reviews Glycoconjugates of Quinolines: Application in Medicinal Chemistry
Mini-Reviews in Medicinal Chemistry Use of Osmotic Dehydration to Improve Fruits and Vegetables Quality During Processing
Recent Patents on Food, Nutrition & Agriculture Selective Serotonin Re-Uptake Inhibitors and Hyponatremia in Acutely Medically-Ill Inpatients
Current Drug Safety